Accelerating life-saving cancer research

Sus Clinicals accelerates qualification of potentially life-saving cancer therapeutics through our proprietary pig-based preclinical testing services. In collaboration with top research institutions with large animal testing capability, our predictive model can better identify those drugs, diagnostics, and devices that have the highest potential for success in human clinical trials.

Get in touch
Learn about our models
Service Delivery Models

Multiple Pathways to Oncopig Research

Sus Clinicals works with our clients to design research programs that fit their specific needs and existing infrastructure. We provide flexible engagement models whether you work with CRO partners or conduct studies in-house.
CRO Partnership Model

Our preferred service delivery approach leverages partnerships with top-tier clinical research organizations equipped with the expertise, facilities, and regulatory compliance needed for rigorous Oncopig studies.

  • Expert study design and execution
  • Regulatory compliance and documentation
  • Comprehensive data and sample management
  • AAALAC-accredited facilities
Direct Institution Supply

For academic and industry clients with established animal research facilities, we provide Oncopigs directly along with comprehensive training and ongoing technical support.

  • Direct Oncopig supply and logistics
  • Tumor induction training
  • Methodology guidance and consultation
  • On-site technical assistance available
European Research Services

Through our partnership with Versa Biomedical in Barcelona, we deliver localized Oncopig research services to clients in Europe, combining our platform expertise with regional infrastructure and expertise.

  • Local European CRO expertise
  • Streamlined logistics and compliance
  • Sus Clinicals oversight and guidance
  • Integrated scientific support

North American CRO Partners

We work with leading contract research organizations that bring specialized expertise in preclinical oncology research, regulatory compliance, and animal welfare. Our CRO partners possess the necessary equipment, facilities, personnel, and quality systems to design and execute rigorous Oncopig-based studies delivering the data, imaging, biological samples, and other deliverables required to advance your research program.
Our Preferred CRO Partners

Each partner brings deep expertise and AAALAC accreditation to ensure the highest standards of study execution and animal care.

CBSET

NAMSA

MED Institute

Veranex

Sus Clinicals recognizes that many clients have established relationships with CROs beyond our preferred partner network. We are committed to engaging with any qualified research organization and readily provide training, technical guidance, and support to ensure successful Oncopig-based research outcomes.

Our Role in Partnership Success

Across all service delivery models, Sus Clinicals maintains close collaboration with our partners to ensure optimal research outcomes. We provide:

  • Expert guidance on Oncopig platform capabilities and limitations
  • Detailed methodology training on tumor induction and management procedures
  • Scientific consultation on study design and endpoint selection
  • Ongoing technical support throughout study execution
  • Quality assurance and regulatory compliance oversight

Upcoming events

News and publications

About us

Sus Clinicals (“Sus” rhymes with “moose”) is named for the genus of wild and domestic pigs (Sus scrofa). We make use of the remarkable similarity between pigs and humans to help our healthcare client partners develop breakthrough therapeutics more efficiently and more quickly, helping to save lives. Our proprietary large animal genome editing research platform is FDA-cleared and accelerates preclinical research. We aim to bridge the gap between fast but minimally predictive mouse-based testing and costly, time-consuming, and high-risk human clinical trials.

Our genetically-engineered Oncopig® enables testing of medical devices, diagnostics, and drugs to assess their efficacy and safety in humans by inducing relevant tumors and comorbidities on demand. Although our initial focus is on cancer, our porcine platform is well-suited to support work against a full spectrum of diseases in the future.

Our story

Ready to Accelerate Your Research Program?

Contact us to discuss how Oncopig-based research services can advance your preclinical development needs.

Connect with an expert